Accelerating projects on access to medicines, support for vulnerable communities, environmental conservation, and diversity and inclusion Creation of Sanofi Global Health, global nonprofit unit to provide 40 of the world’s poorest countries access to 30 essential medicines (PRESS RELEASE) PARIS, 7-Apr-2021 — … Read the full press release
Posted in France, Healthcare, News, Non Profit, Pharma & Biotech, Society
Tagged access to medicines, Cancer, cardiovascular disease, chronic diseases, climate change, Corporate Social Responsibility, CSR strategy, Diabetes, diversity, environmental protection program, Fabry, Gaucher, healthcare professionals, Inclusion, malaria, nonprofit unit, open letter, Paul Hudson, Pharmaceutical, Planet Mobilization, polio, Pompe diseases, preservation of the environment, rare diseases, Sanofi, Sanofi Global Health, sleeping sickness, support for vulnerable communities, tuberculosis, vaccines, WHO, World Health Organization, Zero plastic packaging
(PRESS RELEASE) PARIS/ CAMBRIDGE, 11-Jan-2021 — /EuropaWire/ — French multinational pharmaceutical company Sanofi to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics. The agreement includes an upfront payment … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acquisition, antibody for inflammatory disorders, antibody technologies, atopic dermatitis, biopharmaceutical, biopharmaceutical company, EASI, Eczema Area and Severity Index, fully human antibodies, Goodwin PLC, Gotshal & Manges LLP, human monoclonal antibodies, human monoclonal antibody, ICOS agonist monoclonal antibody, immune regulator, immune-mediated diseases, immuno-oncology therapeutics, inflammatory disorders, J.P. Morgan, John Reed M.D. Ph.D., KY1005, KY1044, Kymab, novel therapies, OX40-Ligand, OX40L, Paul Hudson, Sanofi, Simon Sturge, topical corticosteroids, Weil
Agreement signed today supports scale-up of manufacturing capabilities in several European countries Vaccine candidate uses Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system (PRESS RELEASE) PARIS, 18-Sep-2020 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused … Read the full press release
Posted in Belgium, European Union, France, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Advanced purchase agreement, COVID-19, COVID-19 vaccine, EC, European Commission, GSK, influenza vaccine, Sanofi, vaccine
Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a hedgehog inhibitor in a prospective trial 31% objective response rate seen in trial patients, and an estimated 85% of responses … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science
Tagged advanced basal cell carcinoma, Alexander Stratigos M.D., Andreas Sygros Hospital, basal cell carcinoma, BCC, biopharmaceutical, cemiplimab, ESMO Virtual Congress 2020, European Society for Medical Oncology, hedgehog inhibitor, HHI therapy, inhibitor, Libtayo®, Regeneron, Sanofi, University of Athens Medical School
(PRESS RELEASE) PARIS, 18-Sep-2020 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced it has appointed Dr. Jean-Christophe Rufin as President of the Sanofi Espoir Corporate Foundation, aimed at reducing inequalities in health … Read the full press release
Posted in France, Healthcare, Management, News, Pharma & Biotech, Society
Tagged access to healthcare, appointment, Brazilian Academy of Letters, Catholic University of Louvain, Dr. Jean-Christophe Rufin, fight against pediatric cancers, Laval University, reduce health inequalities, Royal Academy of Medicine of Belgium, Sanofi, Sanofi Espoir Corporate Foundation, Serge Weinberg, Xavier Darcos
(PRESS RELEASE) PARIS, 28-Aug-2020 — /EuropaWire/ — French multinational pharmaceutical company Sanofi announces its intention to commence a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of Principia Biopharma Inc. for $100 per share … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech
Tagged acquisition, biopharmaceutical, BofA Securities, BTK inhibitor, Centerview Partners LLC, Cooley LLP, Evercore, Gotshal & Manges LLP, Healthcare, immune thrombocytopenia, immune-mediated diseases, ITP, Kortex Acquisition Corp., MERGER, Merger Agreement, outstanding shares, Principia Biopharma Inc., rilzabrutinib, Sanofi, stock, Tailored Covalency®, tender offer, Weil
Further strengthens core R&D areas of autoimmune and allergic diseases Provides full control of brain-penetrant BTK inhibitor SAR442168 in multiple sclerosis (MS), making commercialization more efficient and eliminating future royalty payments Allows expansion of SAR442168 development program into other central … Read the full press release
Posted in Business, France, Healthcare, Investment, News, Pharma & Biotech
Tagged acquisition, allergic diseases, Arnaud Delepine, Ashleigh Koss, autoimmune diseases, biopharmaceutical, BofA Securities, Bruton tyrosine kinase, BTK inhibitor, BTK inhibitor ‘168, Centerview Partners LLC, Christopher Chai, commercialization, Cooley LLP, Eva Schaefer-Jansen, Evercore, Fara Berkowitz, Felix Lauscher, Gotshal & Manges LLP, John Reed M.D. Ph.D., Martin Babler, MS, multiple sclerosis, Nicolas Kressmann, pathophysiology, Paul Hudson, Paul Laland, Pharmaceutical, Principia, Principia Biopharma, PRN473 Topical, rilzabrutinib, Sanofi, SAR442168, Suzanne Greco, Weil, Yvonne Naughton
Sanofi to provide Plaquenil® (hydroxychloroquine) wherever possible, while securing appropriate supply levels for current approved indications; The company already increased its production capacity by 50% and is on track to further increase production over the coming months; Ongoing global clinical … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Society, Technology
Tagged coronavirus, COVID-19, donation, hydroxychloroquine, Paul Hudson, Plaquenil, Sanofi
(PRESS RELEASE) PARIS and LEXINGTON, MA, U.S.A, 27-Mar-2020 — /EuropaWire/ — Sanofi Pasteur collaborates with Translate Bio (NASDAQ: TBIO) to develop a novel mRNA vaccine for COVID-19. Both companies will jointly investigate multiple candidates with the goal of advancing an … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science
Tagged BARDA, Biomedical Advanced Research and Development Authority, COVID-19, David Loew, infectious diseases, messenger RNA, mRNA, novel mRNA vaccine, pandemic response, Ronald Renaud, Sanofi, Sanofi Pasteur, SARS-CoV-2 vaccine candidates, therapeutics, Translate Bio, vaccines
PARIS, 04-Oct-2018 — /EuropaWire/ — Sanofi has completed the previously announced divestment of its European generics business Zentiva to Advent International (Advent) effective September 30. The transaction was finalized ahead of schedule for €1,9 billion (enterprise value). Sanofi announced the beginning … Read the full press release
Posted in Business, France, Pharma & Biotech
Tagged Advent, divestment, generics, Sanofi, Zentiva
A plan taking place in almost 80 countries Subscription per five shares entitle the employee to one matching share[1] PARIS, 12-Jun-2018 — /EuropaWire/ — Sanofi launches today “Action 2018”, a worldwide stock purchase plan reserved for its employees. In doing such a … Read the full press release
Posted in France, Investment, Management, Pharma & Biotech
Tagged biopharma, Employees, health, Sanofi, shares, stock purchase plan, stock_purchase
Results showed Dupixent demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials in a broad population of patients with uncontrolled asthma, irrespective of minimum baseline eosinophil levels or other biomarkers of Type 2 inflammation Greater … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged asthma, corticosteroids, Dupixent, New England Journal of Medicine, Sanofi
PARIS, 25-Apr-2018 — /EuropaWire/ — Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post … Read the full press release
Posted in France, Healthcare, Management, Pharma & Biotech
Tagged appointment, biopharmaceutical, Elias Zerhouni M.D., John C. Reed M.D. Ph.D., leadership, Management, Sanofi
PARIS, 26-Feb-2018 — /EuropaWire/ — Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi’s proposed acquisition of Bioverativ Inc. (“Bioverativ”, NASDAQ: BIVV) has expired. On February 7, … Read the full press release
Posted in Business, France, Pharma & Biotech
Tagged acquisition, ANTITRUST, Bioverativ, Hart-Scott-Rodino Antitrust Improvements Act, Healthcare, HSRAct, Sanofi
Expands Sanofi’s presence in specialty care and strengthens leadership in rare diseases Adds leader in the growing hemophilia market and provides platform for expansion in other rare blood disorders Drives meaningful shareholder value with ROIC expected to exceed cost of … Read the full press release
First head-to-head randomized clinical trial comparing the efficacy and safety of Toujeo (insulin glargine 300 Units/mL) versus insulin degludec PARIS, 05-Dec-2017 — /EuropaWire/ — Sanofi’s Toujeo® met the primary study objective in the first large head-to-head clinical trial1, called BRIGHT study, … Read the full press release
Posted in France, Healthcare, Pharma & Biotech, Technology
Tagged insulin degludec, Riccardo Perfetti, Sanofi, The BRIGHT study, Toujeo®
PARIS, 05-Dec-2017 — /EuropaWire/ — Following a planned interim analysis, the Independent Data Monitoring Committee (IDMC) for the phase III Cdiffense clinical trial program concluded that the probability that the study will meet its primary objective is low. Based on this, Sanofi has … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged Clostridium difficile vaccine, Sanofi, Sanofi Pasteur
LONDON, 01-Dec-2017 — /EuropaWire/ — On December 5-6, 2017, 200 high-level experts from government, academia, biopharmaceutical developers and patient organisations convene in London (UK) to address the mounting challenge of accessibility and patient access to high-value, high-cost medical therapies. The … Read the full press release
Posted in Government, Healthcare, News, Non Profit, Pharma & Biotech, Science, Society, United Kingdom
Tagged academia, Aetna, analytica|LASER, auto-immune diseases, biopharmaceutical, biopharmaceutical developers, Cancer, deadly HIV epidemic, Dr. Harold Paz, Dr. Olivier Brandicourt, Dr. Sarah Garner, drug developers, drug policy, EURORDIS-Rare Diseases Europe, French HAS, global health systems sustainability, government, health ministries, health systems, Healthcare, high-cost medical therapies, high-value medicines, Julia Corner, life-saving drugs, London School of Hygiene and Tropical Medicine, medicine access, medicine accessibility, National Institute for Health and Care Excellence, not-for-profit event, patient access, patient organisations, Pharmaceutical, Prof Peter Piot, Prof. Dominique Le Guludec, Prof. Lucien Abenhaim, rare disease, rare diseases, Renaissance St Pancras Hotel, Sanofi, Sir Andrew Dillon, Ulrich Neumann, World Health Organization, Yann Le Cam
First study with a biologic to show benefit in severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil levels or any other Type 2 biomarkers at baseline Pivotal program is first with a biologic to show consistent reductions … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged dupilumab, Sanofi, steroid-dependent asthma
PARIS, 10-Aug-2017 — /EuropaWire/ — Sanofi announced today that it filed a patent infringement suit against Merck Sharp & Dohme Corp. (“Merck”) on August 8, 2017 in the United States District Court for the District of New Jersey. In its suit Sanofi … Read the full press release
Posted in France, Pharma & Biotech
Tagged Merck Sharp & Dohme Corp., Sanofi
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?